

CUMULATIVE TABLE OF CONTENTS, VOLUME 17

Number 1

THROMBOLYSIS OF ACUTE AND CHRONIC ARTERIAL OCCLUSIONS

Michael Martin, M.D.

Fibrinolytic Therapy: Biochemical Mechanisms, Kenneth C. Robbins, Ph.D.

Thrombolysis in Arterial Bypass Grafts, Arina van Breda, M.D.

Local Thrombolysis for Salvage of Occluded Bypass Grafts, Klaus Mathias, M.D.

Short-Term Ultrahigh Streptokinase Treatment of Chronic Arterial Occlusions and Acute Deep Vein Thromboses, Michael Martin, M.D., and B.J. Othmar Fiebach, M.D.

Intra-Arterial Fibrinolytic Therapy of Chronic Arterial Occlusions, Franz-Joseph Roth, M.D., Rudolf Rieser, M.D., Anders Scheffler, M.D., and Wolfgang Krings, M.D.

Fibrinolytic Therapy of Deep Vein Thrombosis with Continuous Intravenous Infusion of a Recombinant Tissue Plasminogen Activator, Rainer Zimmerman, M.D., Abdulkadir Gürsoy, M.D., Andreas Horn, M.D., Job Harenberg, M.D., Curt Diehm, M.D., and Wolfgang, Kübler, M.D.

Factor XI: A Review of Its Biochemistry and Deficiency, Craig S. Kitchens, M.D.

Abstracts of Current Literature, Rodger L. Bick, M.D., F.A.C.P., Genesio Murano, Ph.D., Meyer M. Samama, M.D., and Ernst Wenzel, M.D., Editors

Number 2

HIRUDIN

Fritz Markwardt, M.D., Ph.D.

The Comeback of Hirudin as an Antithrombotic Agent, Fritz Markwardt, M.D., Ph.D.

Isolation and Characterization of Hirudin from *Hirudo medicinalis*, Peter Walsmann, Ph.D.

Recombinant Hirudin: Genetic Engineering and Structure Analysis, Walter E. Märki, Hugo Grossenbacher, Markus G. Grütter, Manfred H. Liersch, Bernd Meyhack, and Jutta Heim

Structure-Activity Relationships of Recombinant Hirudins, Jörg Stürzebecher, Ph.D., and Peter Walsmann, Ph.D.

Methods for Determination of Hirudin, Jörg Stürzebecher, Ph.D.

Comparative Studies on Various Assays for the Laboratory Evaluation of r-Hirudin, Jeanine M. Walenga, Ph.D., MT (ASCP), Debra Hoppensteadt, M.S., MT (ASCP), Michael Koza, B.S., MT (ASCP), Roque Pifarre, M.D., and Jawed Fareed, Ph.D.

Laboratory Use of Hirudin, Kurt Stocker, Ph.D. hon.

Hirudin and Platelets, Erika Glusa, M.D.

Toxicology of Hirudin, Hans-Peter Klöcking, M.D., D.Sc.

Anticoagulant and Antithrombotic Actions of Recombinant Hirudin, Brigitte Kaiser, M.D.

Neutralization of Recombinant Hirudin: Some Practical Considerations, Jawed Fareed, M.D., Jeanine M. Walenga, Ph.D., Debra Hoppensteadt, M.S., Lalitha Iyer, B.S., and Roque Pifarre, M.D.

Pharmacokinetics of Hirudin, Goetz Nowak, M.D.

Report on a Discussion Forum: "Medical and Surgical Application of Recombinant Hirudin", Jeanine M. Walenga, Ph.D., Fritz Markwardt, M.D., Klaus Breddin, M.D., Jawed Fareed, M.D. (Organizing Committee)

Scholarly Potpourri, Ernst Wenzel, M.D.

Number 3

CELL BIOLOGY OF FIBRINOLYSIS

Hau C. Kwaan, M.D., and Gabor Markus, M.D., Ph.D.

Fibrinolysis: Past and Present, a Reflection of Fifty Years, Tage Astrup, Dr. Scient., Dr. Med. h.c.

Components of the Plasminogen-Plasmin System in Human Tumor Cell Lines, Hau C. Kwaan, M.D., Harold N. Keer, M.D., James A. Radosevich, Ph.D., Jean-Francois Cajot, M.D., and Robin Ernst, B.S.

Protein Structure and Membrane Anchorage of the Cellular Receptor for Urokinase-Type Plasminogen Activator, Michael Ploug, Ph.D., Niels Behrendt, Ph.D., Dorte Løber, M.S., and Keld Danø, M.D.

Plasminogen Activation by Receptor-Bound Urokinase, Vincent Ellis, Ph.D., and Keld Danø, M.D.

Stimulation of Cell Surface Plasminogen Activation by Heparin and Related Polyionic Substances, Ross W. Stephens, Ph.D., Jari Pöllänen, M.D., Hannele Tapiovaara, M.Sc., Graeme Woodrow, Ph.D., and Antti Vaheri, M.D., Ph.D.

Plasminogen Activators in Epithelial Biology, Gerald S. Lazarus, M.D., and Pamela J. Jensen, Ph.D.

Epidermal Growth Factor and 12-Tetradecanoyl Phorbol 13-Acetate Induction of Urokinase in A431 Cells, Timothy L. Kessler, Ph.D., and Gabor Markus, M.D., Ph.D.

Urokinase-Dependent Proteolysis in Cultured Colon Cancer Is Directed by Its Receptor, William Hollas, B.A., and Douglas Boyd, Ph.D.

Growth Factors in the Regulation of Plasminogen-Plasmin System in Tumor Cells, Jorma Keski-Oja, M.D., Katri Koli, M.Sc., Jouko Lohi, B.M., and Marikki Laiho, M.D.

Tumor Necrosis Factor Stimulates Urokinase-Type Plasminogen Activator and Inhibitor Type 1 Production in A549 Lung Carcinoma Cells: Treatment of Monolayer and Tridimensional Cultures, Anne-Marie Dosne, Ph.D., René Beaupain, Ph.D., and Meyer Samama, M.D.

Function of Receptor-Bound Urokinase, Johannes C. Kirchheimer, M.D., and Bernd R. Binder, M.D.

Enhanced Activation of Prourokinase by Human RC2A Leukemia Cells, Hannele Tapiovaara, M.Sc., Antti Vaheri, M.D., Ph.D., Riitta Alitalo, M.D., Ph.D., Pheng-Siew Sim, Ph.D., Graeme Woodrow, Ph.D., and Ross W. Stephens, Ph.D.

Modulation of Surface-Associated Urokinase in Different Cell Lines: Evidence for Urokinase Interiorization and Degradation, Mario Del Rosso, M.D., Gabriella Fibbi, Ph.D., Germana Dini, Ph.D., Cecilia Grappone, Ph.D. and Marco Pucci, Ph.D.

Regulation of Plasminogen Activator and Plasminogen Activator Inhibitor Expression by Cells of Neural Origin, Patricia G. Murphy, Ph.D., and David A. Hart, Ph.D.

Plasminogen Activator Inhibitor in Stomach and Colorectal Carcinomas, Hideharu Fukao, Ph.D., Nobuya Tanaka, M.D., Shigeru Ueshima, M.D., Ph.D., Kiyotaka Okada, Ph.D., Masayuki Yasutomi, M.D., Ph.D., and Osamu Matsuo, M.D., Ph.D.

Fibrinolytic Profiles in Patients with Small Cell Carcinoma of the Lung, Takeshi Wajima, M.D., Ph.D.

Hormone Regulation of Tissue-Type Plasminogen Activator Gene Expression and Plasminogen Activator-Mediated Proteolysis, Monica Ohlsson, B.S., Xiao-Rong Peng, M.S., Yi-Yun Liu, Ph.D., Xiao-Chi Jia, B.S., Aaron J.W. Hsueh, Ph.D., and Tor Ny, Ph.D.

Fluorescent Probes as Tools to Assess the Receptor for the Urokinase-Type Plasminogen Activator on Tumor Cells, Manfred Schmitt, Ph.D., Nikolaus Chucholowski, Pharm., Elisabeth Busch, BTA, Daniela Hellmann, VMTA, Bettina Wagner, Dipl. Biol., Lothar Goretzki, Dipl. Biol., Fritz Jänicke, M.D., Wolfgang A. Günzler, Ph.D., and Henner Graeff, M.D.

Clinical Relevance of the Urokinase-Type and Tissue-Type Plasminogen Activators and of Their Type I Inhibitor in Breast Cancer, Fritz Jänicke, M.D., Manfred Schmitt, Ph.D., and Henner Graeff, M.D.

Abstracts of Current Literature, Rodger L. Bick, M.D., F.A.C.P., Genesio Murano, Ph.D., Meyer M. Samama, M.D., and Ernst Wenzel, M.D., Editors

Scholarly Potpourri, Genesio Murano, Ph.D.

Number 4

THROMBOSIS AND FIBRINOLYSIS: CURRENT CLINICAL AND THERAPEUTIC ASPECTS

Jawed Fareed, Ph.D., Hau C. Kwaan, M.D.,
Pan Ganguly, M.D., Jeanine M. Walenga, Ph.D.,
H. Klaus Breddin, M.D., and Antonio Strano, M.D.

Venous Thromboprophylaxis in the 1990s: A Perspective, Jawed Fareed, Ph.D.

International Perspective on Venous Thromboembolism Prophylaxis in Surgery, Juan I. Arcelus, M.D., Ph.D., Joseph A. Caprini, M.D., F.A.C.S., and Clara I. Traverso, M.D., Ph.D.

Is Pulmonary Embolism a Suitable Evaluation Criterion of the Efficacy of Prophylactic Treatment in Surgery?, Francis Toulemonde, M.D., and Christian Dautrempuich, M.D.

Current Trends in the Management of Postsurgical Thromboembolism: The Role of Low Molecular Weight Heparin, David Bergqvist, M.D., Ph.D.

Thromboprophylaxis with Heparin and Low Molecular Weight Heparin in Elective Hip Surgery: Current Status and Perspectives, Hans Georg Breyer, M.D.

Comparison of the Efficacy and Safety of Sandoz Low Molecular Weight Heparin and Unfractionated Heparin: Interim Analysis of a Multicenter Trial, Helmut Wolf, M.D., Albrecht Encke, M.D., Sylvia Haas, M.D., and Dieter Welzel, M.D.

Prevention of Thromboembolism After Spinal Cord Injury, David Green, M.D., Ph.D.

Can the Bleeding Potential of Low Molecular Weight Heparins be Assessed and Minimized in Postsurgery Prophylaxis?, Francis Toulemonde, M.D.

Low Molecular Weight Heparins and External Pneumatic Compression as Options for Venous Thromboembolism Prophylaxis: A Surgeon's Perspective, Joseph A. Caprini, M.D., F.A.C.S., Juan I. Arcelus, M.D., Ph.D., Clara I. Traverso, M.D., Ph.D., and James H. Hasty, Ph.D.

A Pilot Study on the Use of a Low Molecular Weight Heparin (Enoxaparin) in Arterial Reconstructive Surgery, Charles Marc Samama, M.D., Eric Barre, M.D., Sophie Combe, M.D., Sophie Dreux, M.D., Edouard Kieffer, M.D., and Pierre Viars, M.D.

Heparins and Stroke: Is There a Place for Low Molecular Weight Heparins?, William S. Fields, M.D.

Effect of Pentosan Polysulfate on Fibrinolysis: Basic Tests and Clinical Application, Helmut Vinazzer, M.D.

Influence of Hypersulfated Lactobionic Acid Amides on Tissue

Plasminogen Activator Release, Hans-Peter Klöcking, M.D., D.Sc., Anna Hoffmann, D.Sc., and Jawed Fareed, Ph.D.

Advantages of Low Molecular Weight Heparin over Standard Heparin: Facts and Fiction, Helmut Vinazzer, M.D.

Effect of Heparin on the Fibrinolytic Response to Plasminogen Activators, Robin Fears, Ph.D., Ashiq F. Esmail, Ph.D., and Helen C. Greenwood, M.I. Biol.

Effect of Pentosan Polysulfate on Activated Partial Thromboplastin Time, Thrombin Time, Euglobulin Clot Lysis, and on Tissue-Type Plasminogen Activator and Plasminogen Activator Inhibitor Activities in Patients with Thromboembolic Disease, Hajna Losonczy, M.D., Ph.D., Marianna Dávid, M.D., and Ibolya Nagy, M.D., Ph.D.

Enhancement by Defibrotide of Prostanoid Neosynthesis from Arachidonic Acid: An Adenosine Receptor-Mediated Effect?, Giorgio Bianchi, M.D., Angelo Benvenuto Calvani, Marisa Mantovani, M.D., and Giuseppe Prino, M.D.

Absorption Through the Peritoneum of the Macromolecular Fibrinolytic Drug Defibrotide in the Rabbit, Roberto Porta, Ph.D., Angelo Benvenuto Calvani, Rodolfo Pescador, Ph.D., Marisa Mantovani, M.D., and Giuseppe Prino, M.D.

Fibrinolytic Activity in Patients with Diabetes Mellitus: Characterization of the Effects of Thrombolytic Agents on Plasma Clot Lysis In Vitro, Robin Fears, Ph.D., Ruth Strandberg, Ph.D., and Ralph Abraham, Ph.D., B.M., B.Ch., M.R.C.P.

Induction and Possible Role of Fibrinolysis in Diabetes Mellitus, Jørgen Gram, M.D., D.Sc., and Jørgen Jespersen, M.D., D.Sc.

Plasminogen Activation in Diabetes Mellitus: Kinetics of Plasmin Formation with Plasminogen and Tissue Plasminogen Activator from Diabetic Donors, Margarethe Geiger, M.D., and Bernd R. Binder, M.D.

In Vivo Platelet Activation in Diabetes Mellitus, Antonio Strano, M.D., Giovanni Davi, M.D., and Carlo Patrono, M.D.

Nonenzymatic Glycation of Platelet Proteins in Diabetic Patients, Isaac Cohen, Ph.D., Dan L. Burk, M.Sc., Ruth Fullerton, Arthur Veis, Ph.D., and David Green, M.D., Ph.D.

Large Platelets Circulate in an Activated State in Diabetes Mellitus, D. Tschöpe, M.D., P. Roesen, J. Esser, B. Schwippert, H.K. Nieuwenhuis, B. Kehrel, and F.A. Gries

Clinical Trials of Antiplatelet Agents in Diabetes Mellitus: Rationale, and Results, John A. Colwell, M.D., Ph.D.

Modifications of Monocyte Procoagulant Activity in Diabetes Mellitus, Brigitte Jude, M.D., and Pierre Fontaine, M.D.

Diabetic Capillary Angiopathy of the Dermis of the Hand and Foot in Patients with Diabetes Mellitus, Panagiotis Balas, M.D.

Biologic Tolerance of Two Different Low Molecular Weight Heparins, Hanne M. Christiansen, M.D., Michael R. Lassen, M.D., Lars C. Borris, M.D., Jens V. Sørensen, M.D., Hans B. Rahr, M.D., Lars N. Jørgensen, M.D., Peer W. Jørgensen, M.D., and Ole Hauch, M.D.

Some Objective Considerations for the Use of Heparins and Recombinant Hirudin in Percutaneous Transluminal Coronary Angioplasty, Jawed Fareed, Ph.D., Jeanine M. Walenga, Ph.D., F. Leya, M.D., P. Bacher, M.D., Debra Hoppensteadt, M.S., Harry Messmore, M.D., and Roque Pifarre, M.D.

Report on the Chicago Satellite Symposia of the Xth International Congress of Fibrinolysis, August 2-4, 1990

Abstracts of Current Literature, Rodger L. Bick, M.D., F.A.C.P., Genesio Murano, Ph.D., Meyer M. Samama, M.D., and Ernst Wenzel, M.D., Editors

Author Index and Cumulative Table of Contents, Volume 17

